Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal < em > MET < /em > Amplification from Aneuploidy in Diverse Advanced Cancers

This study describes an approach to distinguish focal and non-focal MET amplification using comprehensive genomic profiling of cfDNA in advanced cancer patients. Focal MET amp accounted for ~30% of all MET amp, which was found in 3.7% of patients with diverse cancers and was associated with a higher plasma copy number. Clinical studies are warranted to assess the clinical utility of targeted therapies for tumors with focal MET amplification detected by NGS of cfDNA.PMID:34677235 | PMC:PMC8534719 | DOI:10.3390/curroncol28050317
Source: Current Oncology - Category: Cancer & Oncology Authors: Source Type: research